Efficacy of BNG-1 to Treat Acute Ischemic Stroke

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

129 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2014-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to investigate the efficacy and safety of BNG-1 in patients with ischemic stroke. The efficacy assessment will be based on the functional outcome while the safety will be reviewed by the adverse events and laboratory examinations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke

NCT07163702

Acute Ischemic Stroke

NOT_YET_RECRUITING PHASE2

Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion

NCT06211712

Acute Ischemic Stroke

RECRUITING NA

Intensive Drug Therapy for Ischemic Stroke

NCT05620615

Ischemic Stroke

UNKNOWN

An Exploratory Study of Ganglioside GM1 in Acute Ischemic Stroke

NCT04952064

Stroke, Ischemic

COMPLETED PHASE4

The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke

NCT01684462

Cerebral Infarction

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary endpoint will be performed on the 12 weeks after study drug administered and will compare the favorable rate between treatment with Aspirin alone and combination treatment with BNG-1 and Aspirin in patients with ischemic stroke. The favorable to therapy will be determined if all of the following occurs: alive, Modified Rankin Scale (MRS) \< 3, Barthel Index (BI) \>= 60.

Secondary objectives are to compare the following:

1. Compare the favorable rate at one week after study drug administered and the end of treatment (Week 4) and 4 weeks of follow-up (Week 8) of either Aspirin alone or combination treatment with BNG-1 and Aspirin.
2. Compare the mean change in Barthel Index (BI), at each evaluation time-point of either Aspirin alone or combination treatment with BNG-1 and Aspirin.
3. Compare the mean change in National Institute of Health Stroke Scale (NIHSS) at each evaluation time-point of either Aspirin alone or combination treatment with BNG-1 and Aspirin.
4. Compare the Modified Rankin Scale (MRS) at each evaluation time-point of either Aspirin alone or combination treatment with BNG-1 and Aspirin.
5. Compare the change in Extended Glasgow Outcome Scale (GOS-E) at each evaluation time-point of either Aspirin alone or combination treatment with BNG-1 and Aspirin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BNG-1 plus Aspirin

BNG-1 3 grams TID plus Aspirin 100mg QD for 4 weeks

Group Type ACTIVE_COMPARATOR

BNG-1

Intervention Type DRUG

BNG-1 3 grams TID for 4 weeks

Aspirin

Aspirin 100mg QD for 4 weeks

Group Type SHAM_COMPARATOR

Aspirin

Intervention Type DRUG

Aspirin 100 mg QD for 4 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BNG-1

BNG-1 3 grams TID for 4 weeks

Intervention Type DRUG

Aspirin

Aspirin 100 mg QD for 4 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Both genders and ages 20 through 65 (subjects are at least 20 years old but not yet 66).
2. Clinical diagnosis of ischemic stroke, causing a measurable neurological deficit.
3. Onset of symptoms of ischemic stroke within 10 days of initiation of treatment with the study drug.
4. Patients have a total National Institutes of Health Stroke Scale (NIHSS) between 8 and 22 inclusive by the time of randomization.
5. Patients have a total Barth Index (BI) less than 60 or Modified Rankin Scale (MRS) at least 3 by the time of randomization.
6. No previous history of stroke or previous stroke with Modified Rankin Scale \< 1.
7. Patient must have a CT or MRI examination compatible with the clinical diagnosis of acute ischemic stroke.
8. Signed informed consent from patient or legally authorized representative.

Exclusion Criteria

1. Patient has only major symptoms that are rapidly improving by the time of randomization.
2. History of stroke within the previous 3 months, exclude TIA.
3. Patient has a CT or MRI scan with evidence of a non-ischemic mechanism, subarachnoid hemorrhage, primary intracerebral or intraventricular hemorrhage.
4. Patients with known or suspected prior intracranial haemorrhage or history of brain injury or brain tumor.
5. Patient had documented history of any atrial fibrillation occurring 6 months before randomization.
6. Hypertension, defined as systolic blood pressure \> 185 mmHg or diastolic blood pressure \>110 mmHg or requiring aggressive (eg, intravenous antihypertensive) treatment to reduce blood pressure to within these limits.
7. Recurrent peptic ulcer or gastrointestinal bleeding documented by radiographic or endoscopic means within the past 3 months.
8. Pregnant or lactating women or women of childbearing potential who are not practicing reliable birth control.
9. Platelet count less than 100,000 cells/ml.
10. Activated partial thromboplastin time (aPTT) prolongation greater than 2 seconds above the upper limit of normal for local laboratory.
11. International normalized ratio (INR) greater than or equal to 1.4.
12. Uncontrolled hyperglycemia (Sugar AC \> 200 mg/dl).
13. History of alcohol or drug abuse in the previous 3 months.
14. History of hypersensitivity or intolerance of study drug or aspirin.
15. Neurological (other than the presenting stroke) or psychiatric conditions that may affect the patient's functional status and/or that may interfere with the patient's assessment.
16. Previously in the BRAIN-Study or participation in a research protocol for investigation of a pharmaceutical agent or innovative invasive procedure within the past 30 days.
17. Any other known clinically significant medical disorder (e.g., a severe comorbid disease or dementia, transient cerebral ischemia, lower gastrointestinal bleeding, bleeding diathesis, hepatorenal diseases, cancer, and AIDS).
18. Patients who have received anticoagulant agents, antiplatelet agents (except Aspirin), thrombolytics with 48-hour before randomization.

Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No